click on circles to display study description...
durvalumab plus osimertinib (n=14) vs. osimertinib (n=15)
randomized controlled trial
durvalumab plus osimertinib
durvalumab (10 mg/kg administered intravenously every 2 weeks) plus osimertinib (80 mg once daily)
osimertinib
osimertinib (80 mg once daily)
mNSCLC - L2 - EGFR mutant
Disease progression after EGFR-TKI therapy was mandatory; other lines of therapy also may have been given.
open design
nine centers in South Korea, Canada, and the Republic of China
P3/ no alpha no interim analysis. All results are exploratory. CAURAL recruitment was terminated early because of increased incidence of interstitial lung disease–like events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466).
efficacy related objectives are considered exploratory
powered by vis.js Network